How many insider trades does FilingIQ track for IMRX?

FilingIQ tracks 104 Form 4 insider transactions for IMRX (Immuneering Corp), covering filings from Aug 3, 2021 onwards. 1 of those were filed in the last 90 days.

Are IMRX insiders net buyers or net sellers?

Across the full Form 4 history for IMRX, 60 transactions (58%) were open-market purchases and 13 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IMRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IMRX in?

Immuneering Corp (IMRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $320.27M.

IMRX insider trading

Healthcare

Immuneering Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

104

Last 90 days

Buys / sells

58% / 13%

Market cap

$320.27M

About Immuneering Corp

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Company website: immuneering.com

IMRX insider activity at a glance

FilingIQ has scored 104 insider transactions for IMRX since Aug 3, 2021. The most recent filing in our index is dated Mar 13, 2026.

Across the full history, 60 open-market purchases and 13 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IMRX insider trades is 51.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IMRX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding IMRX

AMERICAN CENTURY COMPANIES INC

$87936 · 0.0% of AUM

Frequently asked

How many insider trades does FilingIQ track for IMRX?: FilingIQ tracks 104 Form 4 insider transactions for IMRX (Immuneering Corp), covering filings from Aug 3, 2021 onwards. 1 of those were filed in the last 90 days.
Are IMRX insiders net buyers or net sellers?: Across the full Form 4 history for IMRX, 60 transactions (58%) were open-market purchases and 13 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IMRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IMRX in?: Immuneering Corp (IMRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $320.27M.

Methodology & sources

Every IMRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.